Id: acc1827
Group: 2sens
Protein: IDO
Gene Symbol: IDO1
Protein Id: P14902
Protein Name: I23O1_HUMAN
PTM: acetylation
Site: unclear
Site Sequence:
Disease Category: Cancer
Disease: Nasopharyngeal Carcinoma
Disease Subtype:
Disease Cellline: CNE2
Disease Info:
Drug: NaB
Drug Info: -
Effect: modulate
Effect Info: "Sodium butyrate (NaB) can downregulate the expression of indoleamine 2,3-dioxygenase (IDO) induced by interferon-gamma (IFN-gamma) in a dose-dependent manner and significantly promote its acetylation and ubiquitination."
Note:
Score: 4.0
Pubmed(PMID): 25854569
Sentence Index:
Sentence:

Sequence & Structure:

MAHAMENSWTISKEYHIDEEVGFALPNPQENLPDFYNDWMFIAKHLPDLIESGQLRERVEKLNMLSIDHLTDHKSQRLARLVLGCITMAYVWGKGHGDVRKVLPRNIAVPYCQLSKKLELPPILVYADCVLANWKKKDPNKPLTYENMDVLFSFRDGDCSKGFFLVSLLVEIAAASAIKVIPTVFKAMQMQERDTLLKALLEIASCLEKALQVFHQIHDHVNPKAFFSVLRIYLSGWKGNPQLSDGLVYEGFWEDPKEFAGGSAGQSSVFQCFDVLLGIQQTAGGGHAAQFLQDMRRYMPPAHRNFLCSLESNPSVREFVLSKGDAGLREAYDACVKALVSLRSYHLQIVTKYILIPASQQPKENKTSEDPSKLEAKGTGGTDLMNFLKTVRSTTEKSLLKEG

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

Target Drug name MOA Phase Status Disease Source
IDO1 EPACADOSTAT Indoleamine 2,3-dioxygenase inhibitor 3 - neoplasm ATC
IDO1 EPACADOSTAT Indoleamine 2,3-dioxygenase inhibitor 3 Active, not recruiting renal cell carcinoma ClinicalTrials
IDO1 EPACADOSTAT Indoleamine 2,3-dioxygenase inhibitor 3 Completed melanoma ClinicalTrials
IDO1 LINRODOSTAT Indoleamine 2,3-dioxygenase inhibitor 3 Completed melanoma ClinicalTrials
IDO1 LINRODOSTAT Indoleamine 2,3-dioxygenase inhibitor 3 Withdrawn non-small cell lung carcinoma ClinicalTrials
IDO1 EPACADOSTAT Indoleamine 2,3-dioxygenase inhibitor 3 Completed urogenital neoplasm ClinicalTrials
ClinicalTrials
IDO1 EPACADOSTAT Indoleamine 2,3-dioxygenase inhibitor 3 Active, not recruiting head and neck malignant neoplasia ClinicalTrials
IDO1 LINRODOSTAT Indoleamine 2,3-dioxygenase inhibitor 3 Withdrawn head and neck malignant neoplasia ClinicalTrials
IDO1 EPACADOSTAT Indoleamine 2,3-dioxygenase inhibitor 3 Withdrawn head and neck malignant neoplasia ClinicalTrials
IDO1 LINRODOSTAT Indoleamine 2,3-dioxygenase inhibitor 3 Completed skin cancer ClinicalTrials
IDO1 EPACADOSTAT Indoleamine 2,3-dioxygenase inhibitor 3 Terminated lung cancer ClinicalTrials
IDO1 LINRODOSTAT Indoleamine 2,3-dioxygenase inhibitor 3 Withdrawn lung cancer ClinicalTrials
IDO1 EPACADOSTAT Indoleamine 2,3-dioxygenase inhibitor 2 Withdrawn head and neck squamous cell carcinoma ClinicalTrials
IDO1 EPACADOSTAT Indoleamine 2,3-dioxygenase inhibitor 2 Terminated head and neck squamous cell carcinoma ClinicalTrials
ClinicalTrials
IDO1 EPACADOSTAT Indoleamine 2,3-dioxygenase inhibitor 2 Completed myelodysplastic syndrome ClinicalTrials
IDO1 LINRODOSTAT Indoleamine 2,3-dioxygenase inhibitor 2 Active, not recruiting oral squamous cell carcinoma ClinicalTrials
IDO1 LINRODOSTAT Indoleamine 2,3-dioxygenase inhibitor 2 Terminated bladder tumor ClinicalTrials
IDO1 EPACADOSTAT Indoleamine 2,3-dioxygenase inhibitor 2 Completed cutaneous melanoma ClinicalTrials
IDO1 EPACADOSTAT Indoleamine 2,3-dioxygenase inhibitor 2 Active, not recruiting sarcoma ClinicalTrials
IDO1 EPACADOSTAT Indoleamine 2,3-dioxygenase inhibitor 2 Withdrawn small cell lung carcinoma ClinicalTrials
IDO1 LINRODOSTAT Indoleamine 2,3-dioxygenase inhibitor 2 Withdrawn melanoma ClinicalTrials
IDO1 EPACADOSTAT Indoleamine 2,3-dioxygenase inhibitor 2 Active, not recruiting ovarian carcinoma ClinicalTrials
IDO1 EPACADOSTAT Indoleamine 2,3-dioxygenase inhibitor 2 Withdrawn head and neck malignant neoplasia ClinicalTrials
IDO1 EPACADOSTAT Indoleamine 2,3-dioxygenase inhibitor 2 Terminated urothelial carcinoma ClinicalTrials
IDO1 EPACADOSTAT Indoleamine 2,3-dioxygenase inhibitor 2 Active, not recruiting pancreatic adenocarcinoma ClinicalTrials

Note: Only show clinically investigational or approved drugs with protein targets.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC

No intensity data of this site,
show all other sites!

DIDO1-Lys1015
Cancer Intensity
BRCA -0.281
COAD
HGSC
ccRCC
GBM -0.089
HNSC
LUAD 0.365
LUSC -1.372
non_ccRCC
PDAC
UCEC 1.377
DIDO1-Lys231
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC
LUAD 0.707
LUSC
non_ccRCC
PDAC
UCEC -0.707
DIDO1-Lys379
Cancer Intensity
BRCA -0.702
COAD
HGSC
ccRCC
GBM -0.118
HNSC
LUAD 1.747
LUSC -0.395
non_ccRCC
PDAC
UCEC -0.533
DIDO1-Lys449
Cancer Intensity
BRCA 0.28
COAD
HGSC
ccRCC
GBM
HNSC
LUAD 0.83
LUSC -1.11
non_ccRCC
PDAC
UCEC
DIDO1-Lys559
Cancer Intensity
BRCA 1.143
COAD
HGSC
ccRCC
GBM
HNSC
LUAD
LUSC -0.428
non_ccRCC
PDAC
UCEC -0.715
DIDO1-Lys626
Cancer Intensity
BRCA -0.981
COAD
HGSC
ccRCC
GBM 1.47
HNSC
LUAD -0.665
LUSC -0.369
non_ccRCC
PDAC
UCEC 0.546

PTM-Disease Association:

source: PTMD
Residue Position State Disease Class PMID
- - U Colorectal cancer Ubiquitination 36163134

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: